Drug Profile
SEP 227900
Alternative Names: SEP-227900Latest Information Update: 22 Jul 2023
Price :
$50
*
At a glance
- Originator Sepracor
- Developer Sumitomo Pharma America
- Class Analgesics
- Mechanism of Action D amino acid oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease; Cognition disorders; Neuropathic pain
Most Recent Events
- 29 Oct 2010 Discontinued - Phase-I for Alzheimer's disease in USA (unspecified route)
- 29 Oct 2010 Discontinued - Phase-I for Cognition disorders in USA (unspecified route)
- 29 Oct 2010 Discontinued - Phase-I for Neuropathic pain in USA (unspecified route)